Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light
In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some in the sector are looking for ways to improve the current technology, while others are eager to move on.Read more:
biospace.comBiotechnology